Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Antimicrobial Resistance & Infection Control
Published in: Antimicrobial Resistance & Infection Control 1/2012

Open Access 01-12-2012 | Commentary

The gut is the epicentre of antibiotic resistance

Author: Jean Carlet

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2012

Login to get access

Abstract

The gut contains very large numbers of bacteria. Changes in the composition of the gut flora, due in particular to antibiotics, can happen silently, leading to the selection of highly resistant bacteria and Candida species. These resistant organisms may remain for months in the gut of the carrier without causing any symptoms or translocate through the gut epithelium, induce healthcare-associated infections, undergo cross-transmission to other individuals, and cause limited outbreaks. Techniques are available to prevent, detect, and treat the carriage of resistant organisms in the gut. However, evidence on these techniques is scant, the only exception being selective digestive decontamination (SDD), which has been extensively studied in neutropenic and ICU patients. After the destruction of resistant colonizing bacteria, which has been successfully obtained in several studies, the gut could be re-colonized with normal faecal flora or probiotics. Studies are warranted to evaluate this concept.
Literature
1.
Carlet J, Collignon P, Goldmann P: Society’s failure to protect a precious resource: antibiotics. Lancet. 2011, 378: 369-371. 10.1016/S0140-6736(11)60401-7.CrossRefPubMed
2.
Hughes JM: Preserving the lifesaving power of antimicrobial agents. Jama. 2011, 305: 1027-1028. 10.1001/jama.2011.279.CrossRefPubMed
3.
Piddock LJ: The crisis of no new antibiotics-what is the way forward. Lancet Infect Dis. 2012, 12: 24953-CrossRef
4.
Bush K, Courvalin P, Gautam D: Tackling antibiotic resistance. Nature reviews/microbiology. 2011, 9: 894-895. 10.1038/nrmicro2693.PubMed
5.
Lowe CF, McGeer A, Muller MP, Katz K, for the Toronto ESBL working group: Decreased susceptibility to non-carbapenem antimicrobials in extended-spectrum-B-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Toronto, Canada. Antimicrob Agents Chemother. 2012, 56: 3977-3980. 10.1128/AAC.00260-12.PubMedCentralCrossRefPubMed
6.
Baquero F, Alvarez-Ortega C, Martinez JL: Ecology and evolution of antibiotic resistance. Envoron Microbial Reports. 2009, 1: 469-476. 10.1111/j.1758-2229.2009.00053.x.CrossRef
7.
Canton R, Akova M, Carmeli Y: Rapid evolution and spread of carbapenemases among enterobacteriaceae in Europe. Cli Microbiol Infect. 2012, 18: 413-431. 10.1111/j.1469-0691.2012.03821.x.CrossRef
8.
Gupta N, Limbago BM, Patel JB, Kallen AJ: Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011, 53: 60-67. 10.1093/cid/cir202.CrossRefPubMed
9.
Bochholz U, Werber D, Bohmer MM: German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med. 2011, 365: 1763-1770. 10.1056/NEJMoa1106482.CrossRef
10.
11.
Calbo E, Freixas N, Xercavins M: Foodborne nosocomial outbreak of SHV1 and CTX-M-15-producing Klebsiella pneumoniae: epidemiology and control. Clin Infect Dis. 2011, 52: 743-749. 10.1093/cid/ciq238.CrossRefPubMed
12.
D’Costa VM, King CE, Kalan L: Antibiotic resistance is ancient. Nature. 2011, 477: 457-461. 10.1038/nature10388.CrossRefPubMed
13.
Levy SB: Microbial resistance to antibiotics. An evolving and persistent problem. Lancet. 1982, 2: 83-88.CrossRefPubMed
14.
Hecker MT, Aron DC, Patel NP, Leymann MK, Donskey CJ: Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med. 2003, 163: 972-978. 10.1001/archinte.163.8.972.CrossRefPubMed
15.
Overdevest I, Willemsen I, Rijnsburger M: Extended-spectrum β-lactamase genes of Escherichia coli in chicken meat and humans, the Netherlands. Emerg Infect Dis. 2011, 17: 1216-1222. 10.3201/eid1707.110209.PubMedCentralCrossRefPubMed
16.
Leverstein-van Hall MA, Dierihx CM, Cohen Stuart J: Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and strains. Clin Microbial Infect. 2011, 17: 873-880. 10.1111/j.1469-0691.2011.03497.x.CrossRef
17.
Vieira AR, Collignon P, Aarestrup FM: Association between antimicrobial resistance in Escherichia coli isolates from food animals and bloodstream isolates from humans in Europe: an ecological study. Foodborne Pathog Dis. 2011, 8: 1295-1301. 10.1089/fpd.2011.0950.CrossRefPubMed
18.
Jarlier V, Trystram D, Brun-Buisson C: Curbing methicillin resistant Staphylococcus aureus in 38 French hospitals through a 15-year institutional program. Arch Intern Med. 2010, 170: 552-559. 10.1001/archinternmed.2010.32.CrossRefPubMed
19.
Cipolla D, Giuffrè M, Mammina C, Corsello L: Prevention of nosocomial infections and surveillance of emerging resistances in NICU. J Matern Fetal Neonatal Med. 2011, 24 (1): 23-26. 10.3109/14767058.2011.607567.CrossRefPubMed
20.
Allegranzi B, Storr J, Dziekan G: The first global patient challenge “Clean care is safer care”: from the lunch to current progress and achievements. J Hosp Infect. 2007, 65 (suppl 2): 115-123.CrossRefPubMed
21.
Forstberg KJ, Reyes A, Wang B: The shared antibiotic resistome of soil bacteria and human pathogens. Science. 2012, 337: 1107-1111. 10.1126/science.1220761.CrossRef
22.
Allen HK, Donato J, Wang HU: Call of the wild: antibiotic resistance genes in natural environments. Nature Reviews/Microbiology. 2010, 8: 251-259. 10.1038/nrmicro2312.PubMed
23.
Tello A, Austin B, Telfer TC: Selective pressure of antibiotic pollution on bacteria of importance to public health. Environ Health Perspect. 2012, 120: 1100-1106. 10.1289/ehp.1104650.PubMedCentralCrossRefPubMed
24.
25.
Cremet L, Bourigault C, Lepelletier D: Nosocomial outbreak of carbapenem-resistant Enterobacter cloacae highlighting the interspecies transferability of the blaOXA-48 gene in the gut flora. J Antimicrob Chemother. 2012, 67: 1041-1043. 10.1093/jac/dkr547.CrossRefPubMed
26.
27.
Stecher B, Denzler R, Maier L: Gut inflammation can boost horizontal gene transfer between pathogenic and commensal Enterobacteriaceae. Proc Natl Acad Sci USA. 2012, 109: 1269-1274. 10.1073/pnas.1113246109.PubMedCentralCrossRefPubMed
28.
Guarino A, Wudy A, Basile F, Ruberto E, Buccigrossi V: Composition and roles of intestinal microbiota in children. J Matern Fetal Neonatal Med. 2012, 25 (Suppl 1): 63-66.CrossRefPubMed
29.
Das P, Singh AK, Pal T: Colonization of the gut with Gram-negative bacilli, its association with neonatal sepsis and its clinical relevance in a developing country. J Med Microbiol. 2011, 60: 1651-1660. 10.1099/jmm.0.033803-0.CrossRefPubMed
30.
Tezuka H, Ohteki T: Regulation of intestinal homeostasis by dendritic cells. Immunol Rev. 2010, 234: 247-258. 10.1111/j.0105-2896.2009.00872.x.CrossRefPubMed
31.
Cremieux AC, Muller-Serieys C, Panhard X: Emergence of resistance in normal human aerobic commensal flora during telithromycin and amoxicillin-clavulanic acid treatments. Antimicrobiol Agents Chemother. 2003, 47: 2030-2035. 10.1128/AAC.47.6.2030-2035.2003.CrossRef
32.
Jemberg C, Loffmark S, Edlund C, Jansson J: Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology. 2010, 156: 3216-3223. 10.1099/mic.0.040618-0.CrossRef
33.
Jeong SH, Song YK, Cho JH: Risk assessment of ciprofloxacin, flavomycin, olaquindox and colistin sulfate based on microbiological impact on human biota. Regul Toxicol Pharmacol. 2009, 53: 209-216. 10.1016/j.yrtph.2009.01.004.CrossRefPubMed
34.
Jakobsson HE, Jemberg C, Andersson AF: Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLos One. 2010, 5: e 9836-CrossRef
35.
Donskey CJ, Chowdhry TK, Hecker MT: Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med. 2000, 343: 1925-1932. 10.1056/NEJM200012283432604.PubMedCentralCrossRefPubMed
36.
Nicolas-Chanoine MH, Gruson C, Bialek-Davenet S: 10-fold increase (2006–11) in the rate of healthy subjects with extended-spectrum B-lactamase-producing Escherichia coli faecal carriage in a Parisian check-up centre. J Antimicrob Chemother. 2012, November 9 Epub ahead of print
37.
Timsit JF, Garrait V, Misset B: The digestive tract as a major site for Acinetobacter baumannii colonization in intensive care unit patients. J Infect Dis. 1993, 168: 1336-1337. 10.1093/infdis/168.5.1336.CrossRefPubMed
38.
Thom KA, Hsiao WW, Harris AD: Patients with Acinetobacter baumannii bloodstream infections are colonized in the gastrointestinal tract with identical strains. Am J Infect Control. 2010, 38: 751-753. 10.1016/j.ajic.2010.03.005.PubMedCentralCrossRefPubMed
39.
Goldstein EJ: Beyond the target pathogen: ecological effects of the hospital formulary. Curr Opin Infect Dis. 2011, 24 (Suppl 1): S21-31. 10.1097/01.qco.0000393485.17894.4c.CrossRefPubMed
40.
Taneja R, Marshall JC: Vasoactive agents and the gut: fueling the motor of multiple organ failure. Crit Care Med. 2000, 28: 3017-3018.CrossRef
41.
van Uffelen R, van Saene HK, Fidler V, Löwenberg A: Oropharyngeal flora as a source of bacteria colonizing the lower airways in patients on artificial ventilation. Intensive Care Med. 1984, 10: 233-237.CrossRefPubMed
42.
Stoutenbeek CP, van Saene HK, Miranda DR, Zandstra DF: A new technique of infection prevention in the intensive care unit by selective digestive decontamination of the digestive tract. Acta Anaesthegiol Belg. 1983, 34: 209-221.
43.
Kesteman AS, Perrin-Guyomard A, Laurenti M: Emergence of resistant Klebsiella pneumoniae in the intestinal tract during successful treatment of Klebsiella pneumoniae lug infection in rats. Antimicrob Agents Chemother. 2010, 54: 2960-2964. 10.1128/AAC.01612-09.PubMedCentralCrossRefPubMed
44.
Lemmens N, van Wamel W, Snijders S: Genomic comparisons of USA 333 Staphylococcus aureus colonizing the nose and rectum in children with skin abscesses. Microbiol Pathog. 2011, 50: 192-199. 10.1016/j.micpath.2010.12.006.CrossRef
45.
Uramatsu M, Matsumoto T, Shibuya K: Involvement of endotoxin in the mortality of mice with gut-derived sepsis due to methicillin-resistant Staphylococcus aureus. Microbiol Immunol. 2010, 54: 330-337. 10.1111/j.1348-0421.2010.00217.x.CrossRefPubMed
46.
Guet-Revillet H, Le Monnier A, Breton N: Environmental contamination with extended-spectrum β-lactamases: is there a difference between Escherichia coli and Klebsiella spp?. Am J Infect Control. 2012, 40: 845-848. 10.1016/j.ajic.2011.10.007.CrossRefPubMed
47.
Stewardson A, Allegranzi B, Sax H, Kilpatrick C, Pittet D: Back to the future: rising to the Semmelweis challenge in hand hygiene. Future Microbiol. 2011, 6: 855-876. 10.2217/fmb.11.66.CrossRefPubMed
48.
Lecky DM, McNulty CA, Adriaenssens N: Development of an educational resource on microbes, hygiene and prudent antibiotic use for junior and senior school children. J Antimicrobial Chemother. 2011, 66 (Suppl 5): 23-31.CrossRef
49.
Sax H, Allegranzi B, Uckay I: ‘My five moments for hand hygiene’: a user-centred design approach to understand, train, monitor and report hand hygiene. J Hosp Infect. 2007, 67: 9-21. 10.1016/j.jhin.2007.06.004.CrossRefPubMed
50.
Kumarasamy KK, Toleman MA, Walsh TR: Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK. A molecular, biological and epidemiological study. Lancet Infect Dis. 2010, 10: 597-602. 10.1016/S1473-3099(10)70143-2.PubMedCentralCrossRefPubMed
51.
Loofts T, Johnson TA, Allen HK: In-feed antibiotic effects on the swine intestinal microbiome. Proc Natl Acad Sci USA. 2012, 109: 1691-1696. 10.1073/pnas.1120238109.CrossRef
52.
De Vries-Hospers HG, Sleifer DT, Mulder NH: Bacteriological aspects of selective decontamination of the digestive tract as a method in infection prevention in granulocytopenic patients. Antimicrob Agents Chemother. 1981, 19: 813-820. 10.1128/AAC.19.5.813.PubMedCentralCrossRefPubMed
53.
Stoutenbeek CP, van Saene HK, Miranda DR, Zandstra DF: The effect of selective decontamination of the digestive tract on colonization and infection rate in multiple trauma patients. Intensive Care Med. 1984, 10: 185-192. 10.1007/BF00259435.CrossRefPubMed
54.
Al-Naemi N, Heddema ER, Bart A: Emergence of multidrug-resistant Gram-negative bacteria during selective decontamination of the digestive tract on an intensive care unit. J Antimicrob Chemother. 2006, 58: 853-856. 10.1093/jac/dkl316.CrossRef
55.
De Smet AM, Kluytmans JA, Blok HE: Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: an open-label clustered group-randomised, crossover study. Lancet Infect Dis. 2011, 11: 372-380. 10.1016/S1473-3099(11)70035-4.CrossRefPubMed
56.
Ochoa-Ardila ME, Garcia-canas A, Gomez-Mediavilla K: Long term use of selective decontamination of the digestive tract does not increase antibiotic resistance: a 5-year prospective cohort study. Intensive Care Med. 2011, 37: 1458-1465. 10.1007/s00134-011-2307-0.CrossRefPubMed
57.
De Smet AM, Kluytmans JA, Cooper BS: Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med. 2009, 360: 20-31. 10.1056/NEJMoa0800394.CrossRefPubMed
58.
De Jonge E, Schultz MJ, Spaniaard L: Effect of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomized controlled trial. Lancet. 2003, 362: 1011-1016. 10.1016/S0140-6736(03)14409-1.CrossRefPubMed
59.
Guandalini S: Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2011, 45 (Suppl): S149-153.CrossRefPubMed
60.
Barth S, Duncker S, Hempe J: Escherichia coli Nissle 1917 for probiotic use in piglets: evidence for intestinal colonization. J Applied Microbiol. 2009, 107: 1697-1710. 10.1111/j.1365-2672.2009.04361.x.CrossRef
61.
Prilassnig M, Wenisch C, Daxboeck F, Feierl G: Are probiotics detectable in human feces after oral uptake by healthy volonteers?. Wien Klin Wochenschr. 2007, 119: 456-462. 10.1007/s00508-007-0808-1.CrossRefPubMed
62.
Joares-Nguyen-Xuan TH, Boehm SK, Joares L: Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers. Inflamm Bowel Dis. 2010, 16: 256-262.CrossRef
63.
Smajs D, Bures J, Chaloupkova E: Experimental administration of the probiotic Escherichia coli strain Nissle 1917 results in decreased diversity of E. coli strains in pigs. Curr Microbiol. 2012, 64: 205-210. 10.1007/s00284-011-0051-x.CrossRefPubMed
64.
Tannock GW, Tiong IS, Priest P: Testing probiotic strain Escherichia coli Nissle 1917 (Mutaflor) for its ability to reduce carriage of multidrug-resistant E. coli by elderly residents in long-term care facilities. J Med Microbiol. 2011, 60: 366-370. 10.1099/jmm.0.025874-0.CrossRefPubMed
65.
Herbrecht R, Nivoix Y: Saccharomyces cerevisiae fungemia: and adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis. 2005, 40: 1635-1637. 10.1086/429926.CrossRefPubMed
66.
Morrow LE, Goginari V, Malesker MA: Probiotic, Prebiotic, and symbiotic in critically ill patients. Curr Opin Crit Care. 2012, 18: 91-CrossRef
67.
Na X, Kelly C: Probiotics in Clostridium difficile infection. J Clin Gastroenterol. 2011, 45: 168-71.CrossRef
68.
Silvestri L, van Saene HK, Gregori D: Probiotics to prevent ventilator-associated pneumonia: no robust evidence from randomized controlled trial. Crit Care Med. 2010, 38: 1616-1617. 10.1097/CCM.0b013e3181dd0a67.CrossRefPubMed
69.
Brun Buisson C, Legrand P, Rauss A: Intestinal decontamination for control of nosocomial multi-resistant gram-negative bacilli. Study of an outbreak in an intensive care unit. Ann Intern Med. 1989, 110: 873-881.CrossRefPubMed
70.
Buehlmann M, Bruderer T, Frei R, Widemer AF: Effectiveness of a new decolonization regimen for eradication of extended-spectrum B-lactamase-producing Enterobacteriaceae. J Hosp Infect. 2011, 77: 113-117. 10.1016/j.jhin.2010.09.022.CrossRefPubMed
71.
Perez F, Pultz M, Endimiani A, Bonomo RA, Donskey CJ: Effect of antibiotic treatment on establishment and elimination of intestinal colonization by KPC-producing Klebsiella pneumoniae in mice. Antimicrob Agents Chemother. 2011, 55: 2585-2589. 10.1128/AAC.00891-10.PubMedCentralCrossRefPubMed
72.
Saides-Odes L, Polachek H, Peled N: A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol. 2012, 33: 14-19. 10.1086/663206.CrossRef
73.
Agusti C, Pujol M, Argerich MJ: Short term effect of the application of selective decontamination of the digestive tract on different body site reservoir ICU patients colonized by multi-resistant Acinetobacter baumanii. J Antimicrobial Chemother. 2002, 49: 205-208. 10.1093/jac/49.1.205.CrossRef
74.
Oostdijk EA, de Smet AM, Kesecioglu J, Bonten MJ, Dutch SOD-SDD trialist group: Decontamination of cephalosporin-resistant Enterobacteriaceae during selective digestive decontamination in intensive care units. J Antimicrob Chemother. 2012, 67: 2250-2253. 10.1093/jac/dks187.CrossRefPubMed
75.
Gough E, Shaikh H, Manges AR: Systematic review of intestinal mocrobiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011, 53: 994-1002. 10.1093/cid/cir632.CrossRefPubMed
76.
Guo B, Harstall C, Louie T: Systematic review: fecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacl Ther. 2012, 35: 865-875. 10.1111/j.1365-2036.2012.05033.x.CrossRef
77.
Russel G, Kaplan J, Ferraro M, Michelow IC: Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Pediatrics. 2010, 126: 239-242. 10.1542/peds.2009-0710.CrossRef
78.
Rosales-Mendoza S, Soria-Guerra RE, Lopez-Revilla R, Moreno-Fieros L, Alpuche-Solis AG: Ingestion of transgenic carrots expressing the Escherichia coli heat-labile enterotoxin B subunit protects mice against cholera toxin challenge. Plant Cell Rep. 2008, 27: 79-84.CrossRefPubMed
79.
Harmoinen J, Mentula S, Heikkila M: Orally administered targeted recombinant B-lactamase prevents ampicillin-induced selective pressure on the gut microbiota: a novel approach to reducing antibacterial resistance. Antimicrob Agents Chemother. 2004, 48: 75-79. 10.1128/AAC.48.1.75-79.2004.PubMedCentralCrossRefPubMed
80.
Tarkkanen AM, Heinonen T, Jogi R: P1A recombinant B-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intra-venous administration of ampicillin. Antimicrob Agents Chemother. 2009, 53: 2455-2462. 10.1128/AAC.00853-08.PubMedCentralCrossRefPubMed
81.
Vos MC, Behrendt MD, Melles DC: Five years of experience implementing a methicillin-resistant Staphylococcus aureus search and destroy policy at the largest University Medical Center in the Netherlands. Infect Control Hosp Epidemiol. 2009, 30: 977-984. 10.1086/605921.CrossRefPubMed
82.
Bocher S, Skov RL, Knudsen MA: The search and destroy strategy prevents spread and long-term carriage of methicillin-resistant Staphylococcus aureus: results from the follow-up screening of a large ST22 (E-MRSA 15) outbreak in Denmark. Clin Microbiol Infect. 2010, 16: 1427-1434. 10.1111/j.1469-0691.2010.03137.x.CrossRefPubMed
83.
Higgins A, Lynch M, Gethin G: Can “search and destroy” reduce nosocomial methicillin-resistant Staphylococcus aureus in an Irish hospital. J Hosp Infect. 2010, 75: 120-123. 10.1016/j.jhin.2009.12.014.CrossRefPubMed
84.
Tosh PK, McDonald LC: Infection control in the multidrug-resistant era: tending the human microbiome. Clin Infect Dis. 2012, 54: 707-713. 10.1093/cid/cir899.CrossRefPubMed
85.
Blaser M: Stop the killing of beneficial bacteria. Nature. 2012, 476: 393-394.CrossRef
86.
Thevenon F, Agatte T, Widdi W, Poté J: Antibiotic resistant bacteria/genes dissemination in lacustrine sediments highly increased following cultural eutrophication of Lake Geneva (Switzerland). Chemosphere. 2012, 86: 468-476. 10.1016/j.chemosphere.2011.09.048.CrossRefPubMed
87.
Schwaber MJ, Lev B, Israeli A: Containment of a country wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis. 2011, 52: 848-855. 10.1093/cid/cir025.CrossRefPubMed
Metadata
Title
The gut is the epicentre of antibiotic resistance
Author
Jean Carlet
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2012
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/2047-2994-1-39

Other articles of this Issue 1/2012

Antimicrobial Resistance & Infection Control 1/2012 Go to the issue

Research

The prevalence of antimicrobial resistance in clinical isolates from Gulf Corporation Council countries

Research

Utility of the first few100 approach during the 2009 influenza A(H1N1) pandemic in the Netherlands

Research

The use of typing methods and infection prevention measures to control a bullous impetigo outbreak on a neonatal ward

Research

Control of antimicrobial resistance in Canada: any lessons to learn?

Short report

Decreasing healthcare-associated infections (HAI) is an efficient method to decrease healthcare-associated Methicillin-resistant S.aureus (MRSA) infections Antimicrobial resistance data from the German national nosocomial surveillance system KISS

Research

A randomized trial to evaluate a launderable bed protection system for hospital beds
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits